// App-Quantinova.ai

LB-069 : Oxaliplatin resistance sensitizes colorectal cancer to TRAIL via death receptor localization

Researchers

Presenter

  • Joshua Dale Greenlee

Principal Investigators

  • Nerymar Ortiz-Otero

  • Tejas Subramanian

  • Kevin Liu

  • Michael King

Medical Centers

  • Vanderbilt University, Nashville, TN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Adrucil injection

  • Oxaliplatin

  • Resveratrol

  • leucovorin

  • Nyamyc

  • Oxaliplatin, 5-fluorouracil and folic acid

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved